Spotlight on “Hot Topics”

The recent reapproval of topical clascoterone in the U.S., the EU, and the U.K. represents a significant expansion of the therapeutic arsenal. Regarding benzoyl peroxide (BPO), the debate over whether the use of BPO-containing products poses a carcinogenic risk was reignited about two years ago. Current data suggest otherwise. Oral isotretinoin is reserved for severe and treatment-resistant forms of acne and has proven to be a highly effective treatment option when certain key principles are followed. What does the current state of knowledge indicate?